TP53 mutations in human cancer: database reassessment and prospects for the next decade.

TP53 mutations are the most frequent genetic alterations found in human cancer. For more than 20 years, TP53 mutation databases have collected over 30,000 somatic mutations from various types of cancer. Analyses of these mutations have led to many types of studies and have improved our knowledge about the TP53 protein and its function. The recent advances in sequencing methodologies and the various cancer genome sequencing projects will lead to a profound shift in database curation and data management. In this paper, we will review the current status of the TP53 mutation database, its application to various fields of research, and how data quality and curation can be improved. We will also discuss how the genetic data will be stored and handled in the future and the consequences for database management.

[1]  Brian H. Dunford-Shore,et al.  Somatic mutations affect key pathways in lung adenocarcinoma , 2008, Nature.

[2]  E. Mardis.  Next-generation DNA sequencing methods. , 2008, Annual review of genomics and human genetics.

[3]  L. Strong,et al.  Gain of Function of a p53 Hot Spot Mutation in a Mouse Model of Li-Fraumeni Syndrome , 2004, Cell.

[4]  M. Hollstein,et al.  Further studies with a cell immortalization assay to investigate the mutation signature of aristolochic acid in human p53 sequences. , 2006, Mutation research.

[5]  T. Soussi.  The history of p53 , 2010, EMBO reports.

[6]  X. Chen,et al.  A proteolytic fragment from the central region of p53 has marked sequence-specific DNA-binding activity when generated from wild-type but not from oncogenic mutant p53 protein. , 1993, Genes & development.

[7]  Alberto Inga,et al.  The expanding universe of p53 targets , 2009, Nature Reviews Cancer.

[8]  G. Evan,et al.  p53 — a Jack of all trades but master of none , 2009, Nature Reviews Cancer.

[9]  M. Kubbutat,et al.  Regulation of Mdm2-Directed Degradation by the C Terminus of p53 , 1998, Molecular and Cellular Biology.

[10]  Toshihide Tsuda,et al.  The TP53 gene, tobacco exposure, and lung cancer , 2003, Human mutation.

[11]  C. Prives,et al.  The C-terminus of p53 binds the N-terminal domain of MDM2 , 2010, Nature Structural &Molecular Biology.

[12]  C. Harris,et al.  Mutations in the p53 tumor suppressor gene: clues to cancer etiology and molecular pathogenesis. , 1994, Cancer research.

[13]  S. Tornaletti,et al.  The distribution of UV photoproducts along the human p53 gene and its relation to mutations in skin cancer. , 1993, Oncogene.

[14]  I. Haviv,et al.  Breast-cancer stromal cells with TP53 mutations. , 2008, The New England journal of medicine.

[15]  C Béroud,et al.  p53 Website and analysis of p53 gene mutations in human cancer: Forging a link between epidemiology and carcinogenesis , 2000, Human mutation.

[16]  S. Kato,et al.  Reassessment of the TP53 mutation database in human disease by data mining with a library of TP53 missense mutations , 2005, Human mutation.

[17]  T. Jacks,et al.  Mutant p53 Gain of Function in Two Mouse Models of Li-Fraumeni Syndrome , 2004, Cell.

[18]  M. Hollstein,et al.  Knock-in mice with a chimeric human/murine p53 gene develop normally and show wild-type p53 responses to DNA damaging agents: a new biomedical research tool , 2001, Oncogene.

[19]  T. Aas,et al.  Specific P53 mutations are associated with de novo resistance to doxorubicin in breast cancer patients , 1996, Nature Medicine.

[20]  Ourania Horaitis,et al.  Time for a unified system of mutation description and reporting: a review of locus-specific mutation databases. , 2002, Genome research.

[21]  T. Soussi,et al.  Analysis of the most representative tumour‐derived p53 mutants reveals that changes in protein conformation are not correlated with loss of transactivation or inhibition of cell proliferation. , 1994, The EMBO journal.

[22]  S. Kato,et al.  The UMD TP53 database and website: update and revisions , 2006, Human mutation.

[23]  I. Haviv,et al.  Breast-Cancer Stromal Cells with TP 53 Mutations , 2008 .

[24]  Ming K. Lee,et al.  Aflatoxin‐B exposure does not lead to p53 mutations but results in enhanced liver cancer of Hupki (human p53 knock‐in) mice , 2006, International journal of cancer.

[25]  Giovanni Parmigiani,et al.  Mutational Analysis of the Tyrosine Phosphatome in Colorectal Cancers , 2004, Science.

[26]  C. Harris,et al.  Increased p53 mutation load in nontumorous human liver of wilson disease and hemochromatosis: oxyradical overload diseases. , 2000, Proceedings of the National Academy of Sciences of the United States of America.

[27]  Jonathan W. Pillow,et al.  POSTER PRESENTATION Open Access , 2013 .

[28]  J. Varley,et al.  Characterization of germline TP53 splicing mutations and their genetic and functional analysis , 2001, Oncogene.

[29]  D. Roukos.  Breast-cancer stromal cells with TP53 mutations. , 2008, The New England journal of medicine.

[30]  Lawrence A. Donehower,et al.  A mutant p53 transgene accelerates tumour development in heterozygous but not nullizygous p53–deficient mice , 1995, Nature Genetics.

[31]  A. Multani,et al.  Chromosome stability, in the absence of apoptosis, is critical for suppression of tumorigenesis in Trp53 mutant mice , 2004, Nature Genetics.

[32]  M. Droege,et al.  Toward a new era in sequencing. , 2007, Biotechnology annual review.

[33]  K. Kinzler,et al.  Identification of p53 as a sequence-specific DNA-binding protein , 1991, Science.

[34]  Kevin M. Ryan,et al.  p53 and metabolism , 2009, Nature Reviews Cancer.

[35]  C. Ishioka,et al.  Locus-specific mutation databases: pitfalls and good practice based on the p53 experience , 2006, Nature Reviews Cancer.

[36]  J. Uhm.  Comprehensive genomic characterization defines human glioblastoma genes and core pathways , 2009 .

[37]  J Milner,et al.  Flexibility: the key to p53 function? , 1995, Trends in biochemical sciences.

[38]  Scott W. Lowe,et al.  Stem cells: The promises and perils of p53 , 2009, Nature.

[39]  E. Pinto,et al.  Founder effect for the highly prevalent R337H mutation of tumor suppressor p53 in Brazilian patients with adrenocortical tumors. , 2004, Arquivos brasileiros de endocrinologia e metabologia.

[40]  S. Gabriel,et al.  Advances in understanding cancer genomes through second-generation sequencing , 2010, Nature Reviews Genetics.

[41]  T. Hudson,et al.  Cancer genomes. , 2010, Clinical chemistry.

[42]  S. Fields,et al.  Two cellular proteins that bind to wild-type but not mutant p53. , 1994, Proceedings of the National Academy of Sciences of the United States of America.

[43]  D. Green,et al.  Dissecting p53-dependent apoptosis , 2006, Cell Death and Differentiation.

[44]  T. Hupp,et al.  The Conformationally Flexible S9–S10 Linker Region in the Core Domain of p53 Contains a Novel MDM2 Binding Site Whose Mutation Increases Ubiquitination of p53 in Vivo * , 2002, The Journal of Biological Chemistry.

[45]  A. Levine,et al.  Mutant p53 gain of function: differential effects of different p53 mutants on resistance of cultured cells to chemotherapy , 1999, Oncogene.

[46]  A. Levine,et al.  The p53 pathway: positive and negative feedback loops , 2005, Oncogene.

[47]  Patrick Dumont,et al.  Mitochondrial p53 activates Bak and causes disruption of a Bak–Mcl1 complex , 2004, Nature Cell Biology.

[48]  Ourania Horaitis,et al.  The challenge of documenting mutation across the genome: The human genome variation society approach , 2004, Human mutation.

[49]  J. Bourdon,et al.  The isoforms of the p53 protein. , 2010, Cold Spring Harbor perspectives in biology.

[50]  M. Tang,et al.  Preferential Formation of Benzo[a]pyrene Adducts at Lung Cancer Mutational Hotspots in P53 , 1996, Science.

[51]  M. Hollstein,et al.  UV-induced DNA damage and mutations in Hupki (human p53 knock-in) mice recapitulate p53 hotspot alterations in sun-exposed human skin. , 2001, Cancer research.

[52]  A. Levine,et al.  The first 30 years of p53: growing ever more complex , 2009, Nature Reviews Cancer.

[53]  A M Gronenborn,et al.  Interhelical angles in the solution structure of the oligomerization domain of p53: correction , 1995, Science.

[54]  Thierry Soussi,et al.  Assessing TP53 status in human tumours to evaluate clinical outcome , 2001, Nature Reviews Cancer.

[55]  E. Birney,et al.  A small cell lung cancer genome reports complex tobacco exposure signatures , 2009, Nature.

[56]  C. Harris,et al.  Oxidative stress and p53 mutations in the carcinogenesis of iron overload-associated hepatocellular carcinoma. , 2001, Journal of the National Cancer Institute.

[57]  C. Prives,et al.  Mutational Analysis of the p53 Core Domain L1 Loop* , 2006, Journal of Biological Chemistry.

[58]  B. Jelaković,et al.  Aristolochic acid and the etiology of endemic (Balkan) nephropathy , 2007, Proceedings of the National Academy of Sciences.

[59]  R. Iggo,et al.  Increased apoptosis induction by 121F mutant p53 , 1999, EMBO Journal.

[60]  J. Simon,et al.  A role for sunlight in skin cancer: UV-induced p53 mutations in squamous cell carcinoma. , 1991, Proceedings of the National Academy of Sciences of the United States of America.

[61]  L. Attardi,et al.  In vivo analysis of p53 tumor suppressor function using genetically engineered mouse models. , 2010, Carcinogenesis.

[62]  P. Jeffrey,et al.  Crystal structure of a p53 tumor suppressor-DNA complex: understanding tumorigenic mutations. , 1994, Science.

[63]  E. Birney,et al.  Patterns of somatic mutation in human cancer genomes , 2007, Nature.

[64]  P. Platzer,et al.  Breast-cancer stromal cells with TP53 mutations and nodal metastases. , 2007, The New England journal of medicine.

[65]  A. Fersht,et al.  Comparative Biophysical Characterization of p53 with the Pro-apoptotic BAK and the Anti-apoptotic BCL-xL* , 2007, Journal of Biological Chemistry.

[66]  Eduardo Sontag,et al.  Transcriptional control of human p53-regulated genes , 2008, Nature Reviews Molecular Cell Biology.

[67]  G. Sal,et al.  p53-family proteins and their regulators: hubs and spokes in tumor suppression , 2010, Cell Death and Differentiation.

[68]  Andrew D. Yates,et al.  A screen of the complete protein kinase gene family identifies diverse patterns of somatic mutations in human breast cancer , 2005, Nature Genetics.

[69]  Mingming Jia,et al.  COSMIC (the Catalogue of Somatic Mutations in Cancer): a resource to investigate acquired mutations in human cancer , 2009, Nucleic Acids Res..

[70]  G. Nolan,et al.  Computational solutions to large-scale data management and analysis , 2010, Nature Reviews Genetics.

[71]  Alan R. Fersht,et al.  Awakening guardian angels: drugging the p53 pathway , 2009, Nature Reviews Cancer.

[72]  O. Halevy,et al.  Different tumor-derived p53 mutants exhibit distinct biological activities. , 1990, Science.

[73]  Lawrence A. Donehower,et al.  20 years studying p53 functions in genetically engineered mice , 2009, Nature Reviews Cancer.

[74]  W. Mcdougal.  An inherited p53 mutation that contributes in a tissue-specific manner to pediatric adrenal cortical carcinoma. , 2002, The Journal of urology.

[75]  M. Metzker.  Sequencing technologies — the next generation , 2010, Nature Reviews Genetics.

[76]  W. Hahn,et al.  Chemosensitivity linked to p73 function. , 2003, Cancer cell.

[77]  T. Soussi,et al.  p53 mutation heterogeneity in cancer. , 2005, Biochemical and biophysical research communications.

[78]  O. Halevy,et al.  Conditional inhibition of transformation and of cell proliferation by a temperature-sensitive mutant of p53 , 1990, Cell.

[79]  J. Minna,et al.  p53: a frequent target for genetic abnormalities in lung cancer. , 1989, Science.

[80]  M. Hollstein,et al.  Murine Fibroblasts Correlate with p 53 Mutations in Human Lung Tumors , 2005 .

[81]  A. Fersht,et al.  Structural biology of the tumor suppressor p53. , 2008, Annual review of biochemistry.

[82]  Thierry Soussi,et al.  Shaping genetic alterations in human cancer: the p53 mutation paradigm. , 2007, Cancer cell.

[83]  A. Puisieux,et al.  Selective targeting of p53 gene mutational hotspots in human cancers by etiologically defined carcinogens. , 1991, Cancer research.

[84]  D. Smith,et al.  p53 point mutation and survival in colorectal cancer patients. , 1995, Cancer research.

[85]  A. Valencia,et al.  From cancer genomes to cancer models: bridging the gaps , 2009, EMBO reports.

[86]  Xin Lu,et al.  ASPP proteins specifically stimulate the apoptotic function of p53. , 2001, Molecular cell.

[87]  A. Fersht,et al.  Thermodynamic stability of wild-type and mutant p53 core domain. , 1997, Proceedings of the National Academy of Sciences of the United States of America.

[88]  D. Ledbetter,et al.  Chromosome 17 deletions and p53 gene mutations in colorectal carcinomas. , 1989, Science.

[89]  T. Soussi,et al.  Splice mutations in the p53 gene: case report and review of the literature , 2003, Human mutation.

[90]  C. Prives,et al.  p 53 Mutants in Mammalian Cells p 73 Function Is Inhibited by Tumor-Derived , 1999 .

[91]  S. Fields,et al.  Distinct residues of human p53 implicated in binding to DNA, simian virus 40 large T antigen, 53BP1, and 53BP2 , 1994, Molecular and cellular biology.

[92]  S. Kato,et al.  Understanding the function–structure and function–mutation relationships of p53 tumor suppressor protein by high-resolution missense mutation analysis , 2003, Proceedings of the National Academy of Sciences of the United States of America.

[93]  C. Harris,et al.  p53 mutations at A:T base pairs in angiosarcomas of vinyl chloride-exposed factory workers. , 1994, Carcinogenesis.

[94]  J. E. Stenger,et al.  p53 domains: identification and characterization of two autonomous DNA-binding regions. , 1993, Genes & development.

[95]  A. Yang,et al.  p63 and p73: p53 mimics, menaces and more , 2000, Nature Reviews Molecular Cell Biology.

[96]  Thierry Soussi,et al.  Analysis of p53 mutation status in human cancer cell lines: a paradigm for cell line cross-contamination , 2008, Cancer biology & therapy.

[97]  A. Levine,et al.  Several hydrophobic amino acids in the p53 amino-terminal domain are required for transcriptional activation, binding to mdm-2 and the adenovirus 5 E1B 55-kD protein. , 1994, Genes & development.

[98]  C. Stratakis,et al.  An inherited p53 mutation that contributes in a tissue-specific manner to pediatric adrenal cortical carcinoma , 2001, Proceedings of the National Academy of Sciences of the United States of America.

[99]  Thierry Soussi,et al.  Significance of TP53 mutations in human cancer: A critical analysis of mutations at CpG dinucleotides , 2003, Human mutation.

[100]  B. Gusterson,et al.  p53 polymorphism influences response in cancer chemotherapy via modulation of p73-dependent apoptosis. , 2003, Cancer cell.

[101]  T. Soussi,et al.  Evolutionary conservation of the biochemical properties of p53: specific interaction of Xenopus laevis p53 with simian virus 40 large T antigen and mammalian heat shock proteins 70 , 1989, Journal of virology.

[102]  C. Pabo,et al.  The DNA-binding domain of p53 contains the four conserved regions and the major mutation hot spots. , 1993, Genes & development.

[103]  B. Gusterson,et al.  A common polymorphism acts as an intragenic modifier of mutant p53 behaviour , 2000, Nature Genetics.

[104]  D. Lane,et al.  Activating mutations in p53 produce a common conformational effect. A monoclonal antibody specific for the mutant form. , 1990, The EMBO journal.

[105]  G. Wahl,et al.  A leucine‐rich nuclear export signal in the p53 tetramerization domain: regulation of subcellular localization and p53 activity by NES masking , 1999, The EMBO journal.

[106]  R. Ribeiro,et al.  A novel mechanism of tumorigenesis involving pH-dependent destabilization of a mutant p53 tetramer , 2002, Nature Structural Biology.

[107]  A. Yang,et al.  Tumor predisposition in mice mutant for p63 and p73: evidence for broader tumor suppressor functions for the p53 family. , 2005, Cancer cell.

[108]  D. Haber,et al.  Cancer: Drivers and passengers , 2007, Nature.

[109]  J. Boeke,et al.  Genetic selection of intragenic suppressor mutations that reverse the effect of common p53 cancer mutations , 1998, The EMBO journal.

[110]  Petr Pancoska,et al.  p53 has a direct apoptogenic role at the mitochondria. , 2003, Molecular cell.

[111]  G. Parmigiani,et al.  The Consensus Coding Sequences of Human Breast and Colorectal Cancers , 2006, Science.

[112]  X. Wang,et al.  TP53 and liver carcinogenesis , 2003, Human mutation.

[113]  C. Harris.  p53: at the crossroads of molecular carcinogenesis and molecular epidemiology. , 1996, The journal of investigative dermatology. Symposium proceedings.

[114]  C. Prives,et al.  A mutant p53 that discriminates between p53-responsive genes cannot induce apoptosis , 1996, Molecular and cellular biology.

[115]  G. Lozano,et al.  Transcriptional activation by wild-type but not transforming mutants of the p53 anti-oncogene. , 1990, Science.

[116]  C. Prives,et al.  The C terminus of p 53 binds the N-terminal domain of MDM 2 , 2010 .

[117]  N. Pavletich,et al.  Structure of the p53 Tumor Suppressor Bound to the Ankyrin and SH3 Domains of 53BP2 , 1996, Science.

[118]  F. Collins,et al.  Mutations in the p53 gene occur in diverse human tumour types , 1989, Nature.